| Drug Name | ***0102 |
| Description |
A novel cancer immunotherapy consists of human peripheral blood mononuclear cells derived T cells transduced with a lentiviral vector encoding a second-generation chimeric antigen receptor targeting CD22. The cell therapy is in early clinical trials for the treatment of acute lymphocytic leukemia. |
| Target | CD22 |
| Drug Modality | CAR-T Cells |
| Indication | Acute Lymphocytic Leukemia |
| Product Category | Cancer Immunotherapy |
| Mechanism of Action | Targeting B-Cell Receptor CD22 |
| Status | Clinical Trials |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial cross-border BD consulting service to encompass segments in equity investment and project incubation.
 |
Protheragen Inc. |
 |
Quick Links |
